References
- Dunn, C J, Plosker, G L, Keating, G M, McKeage, K, Scott, L J. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63:1743–1778. [PUBMED], [INFOTRIEVE]
- Samuels, M H, Eckel, E M. Massive insulin overdose: detailed studies of free insulin levels and glucose requirements. J Toxicol Clin Toxicol 1989; 27:157–168. [PUBMED], [INFOTRIEVE], [CSA]
- Luzio, S D, Beck, P, Owens, D R. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Horm Metab Res 2003; 35:434–438. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Owens, D R, Coates, P A, Luzio, S D, Tinbergen, J P, Kurzhals, R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23:813–819. [PUBMED], [INFOTRIEVE], [CSA]